** Shares of WuXi Biologics (Cayman) Inc 2269.HK climb 4.1% to HK$41.68, their highest level since October 9

** Stock on track for a fifth straight session of gain

** Co expects its 2025 profit attributable to equity shareholders to rise 46.3% y/y to 4.91 bln yuan ($710.21 mln)

** Revenue seen up 16.7% at 21.79 bln yuan and the gross profit margin rate is expected to expand by 5 percentage points to 46%

** Co says the increase is due to enlarged spectrum of services offered to the biologics industry, growth of research services revenue, cost savings and efficiency improvements, among others

** YTD, stock up 29.9%, the Hang Seng Biotech Index .HSBIO up 13.3%

($1 = 6.9106 Chinese yuan)

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))